Research Article

Jianquan You#, Fei Qian#, Yu Huang, Yingxuan Guo, Yaqian Lv, Yuqi Yang, Xiupan Lu, Ting Guo, Jun Wang*, Bin Gu*

**IncRNA WT1-AS attenuates hypoxia/ischemia-induced neuronal injury during cerebral ischemic stroke via miR-186-5p/XIAP axis**

https://doi.org/10.1515/med-2022-0528

received March 29, 2022; accepted June 30, 2022

**Abstract:** This study aimed to investigate the role and mechanism of long non-coding RNA (IncRNA) WT1 antisense RNA (WT1-AS) in cerebral ischemic stroke. The Starbase database and dual-luciferase reporter gene assay were used to analyze the interaction between IncRNA WT1 antisense RNA (IncRNA WT1-AS) and microRNA-186-5p (miR-186-5p). Reverse transcription-quantitative PCR analysis was performed to determine IncRNA WT1-AS and miR-186-5p levels. An oxygen glucose deprivation (OGD)-induced SH-SY5Y cell injury model was established. Cell viability and apoptosis were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and flow cytometric assays, respectively. Caspase 3 activity was evaluated using a caspase 3 activity detection kit. The results showed that miR-186-5p is a direct target of the IncRNA WT1-AS. In addition, IncRNA WT1-AS levels were downregulated and miR-186-5p levels were upregulated in the blood samples of patients with ischemic stroke and OGD-induced SH-SY5Y cells. WT1-AS overexpression promoted OGD-induced cell viability and reduced the cell apoptosis and caspase 3 activity. However, these effects were reversed by miR-186-5p overexpression. Furthermore, the results demonstrated that the X-linked inhibitor of apoptosis (XIAP) was directly targeted by miR-186-5p. Similarly, transfection with the miR-186-5p inhibitor reduced OGD-induced neuronal damage by upregulating XIAP expression. In conclusion, IncRNA WT1-AS attenuates hypoxia/ischemia-induced neuronal injury in cerebral ischemic stroke through the miR-186-5p/XIAP axis.

**Keywords:** wilms tumor 1 antisense RNA, cerebral ischemic stroke, microRNA-186-5p, X-linked inhibitor of apoptosis, oxygen glucose deprivation

1 Introduction

Stroke is the leading cause of cerebral dysfunction and mortality worldwide [1]. Approximately 795,000 new cases of stroke are recorded in the United States annually, while more than 140,000 individuals die from stroke [2]. Eighty percent of stroke cases are attributed to ischemic stroke [3]. The main features of ischemic stroke include interruption of blood flow and lack of oxygen and glucose supply in the brain cells, eventually leading to impaired neuronal cell function. Current treatment approaches for stroke mainly focus on stimulating nerve replacement and timely resolving the infarction to limit continuous hypoxic stress-mediated damage, which eventually results in neuronal injury [4]. To date, the mechanisms and treatment strategies for ischemia/hypoxia-induced neuronal damage remain elusive. Recently, numerous studies have shown that long non-coding RNAs (lncRNAs) and miRNAs are involved in mechanisms underlying ischemia/hypoxia-induced neuronal damage.

lncRNAs are approximately 200 nucleotides in length. Among lncRNAs, genomic DNA can be transcribed into RNA, but it cannot be translated into proteins [5]. lncRNAs play crucial roles in several biological processes, including the regulation of the cell cycle and differentiation and...
epigenetic regulation [6,7]. The roles of various IncRNAs in different diseases have been extensively reported. Several studies have shown that IncRNA expression is upregulated or downregulated in several diseases, including cancer, neurological diseases, and diabetes [8,9]. WT1 antisense RNA (WT1-AS) encodes a zinc finger transcription domain [10]. Emerging evidence has shown that WT1-AS is involved in the onset of numerous types of cancers, including breast cancer, non-small-cell lung cancer, cervical cancer, and glioma [11–14]. This study aimed to investigate the role of WT1-AS in cerebral ischemic stroke.

miRNA is a general term for a class of small non-coding RNAs, ~20–22 nucleotides in length, that are not translated into proteins and inhibit the expression of their target genes [15]. microRNA-186-5p (miR-186-5p), a cancer-related miRNA, is involved in the occurrence and development of several types of cancers [16,17]. Zhu et al. [16] showed that miR-186-5p acts as a tumor suppressor gene that is downregulated in neuroblastoma. In addition, Jones et al. [17] demonstrated that miR-186-5p silencing inhibits the proliferation, growth, and invasion of metastatic cancer cells. Tao et al. [18] indicated that miR-186-5p may be involved in the development of atherosclerosis. However, the role of miR-186-5p in cerebral ischemic stroke has not yet been investigated. Therefore, the current study aimed to investigate whether IncRNA WT1 antisense RNA (IncrNA WT1-AS), miR-186-5p, and X-linked inhibitor of apoptosis (XIAP) could interact with each other and to uncover the underlying mechanism of action of these molecules in cerebral ischemic stroke.

2 Methods

2.1 Clinical samples

Blood samples were obtained from 30 patients with ischemic stroke within 3 h of stroke onset. In addition, 30 blood samples collected from healthy volunteers served as the control group. The characteristics of patients are shown in Table 1. The levels of IncRNA WT1-AS and miR-186-5p in the plasma of patients with ischemic stroke and healthy volunteers were determined using reverse transcription-quantitative PCR (RT-qPCR). Inclusion criteria were as follows: patients who demonstrated new-onset cerebral infarction on magnetic resonance imaging within 3 h from the time of admission were included in the study. The exclusion criteria were evidence of prior cerebral infarcts, diabetes mellitus, coronary artery disease, hypertension, kidney diseases, circulatory disorders, or autoimmune diseases. The study protocol was approved by the Ethics Committee of Taizhou People’s Hospital. All the patients in the current study approved the use of their specimens.

2.2 Dual luciferase reporter assay

The wild-type (WT) or mutant (MUT) 3’-untranslated region (3’-UTR) of WT1-AS were subcloned into the pmirGLO vector (cat. no. E1330; Promega Corporation) to assess the association between WT1-AS and miR-186-5p. Subsequently, 293T cells were co-transfected with miR-186-5p, control mimics, or the above plasmids. Following transfection for 48 h, luciferase activity was measured using a dual-luciferase assay kit (cat. no. E1910; Promega Corporation). To evaluate the association between miR-186-5p and XIAP, XIAP-WT and XIAP-MUT 3’-UTR luciferase reporter plasmids were constructed. Then, 293T cells were co-transfected with Renilla luciferase, luciferase reporter plasmids, and miR-186-5p or control mimics for 48 h. Luciferase activity was determined using a dual luciferase assay kit (Promega Corporation), according to the manufacturer’s instructions.

2.3 Cell culture and transfection

The neuroblastoma cell line, SH-SY5Y, was obtained from the American Tissue Culture Collection (cat. no. CRL-2266). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (both from Gibco; Thermo Fisher Scientific, Inc.) in a cell culture incubator with 5% CO₂ at 37°C. SH-SY5Y cells were then transfected with WT1-AS plasmid, control plasmid, mimic control (5′-UUUCCGAACGUGUCACGUTT-3′; Shanghai GenePharma Co., Ltd., China), miR-186-5p mimics (5′-CAAAAGAUUUCUUCUUGCAGCU-3′; Shanghai GenePharma Co., Ltd., China), WT1-AS plasmid + mimic control, WT1-AS plasmid + miR-186-5p mimics, inhibitor control (5′-GCCUCUGCUUCGACCCUCUCU-3′; Shanghai GenePharma Co., Ltd., China), miR-186-5p inhibitor (5′-AGCCAAAAGAGAAUUCUUUGGGCU-3′; Shanghai GenePharma Co., Ltd., China), control small interfering (si)-RNA, XIAP small-interfering RNA (siRNA), miR-186-5p inhibitor + control siRNA, or miR-186-5p inhibitor + XIAP siRNA for 48 h using Lipofectamine™ 2000 transfection reagent (cat. no. R21101; Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. The cells were incubated for 48 h prior to subsequent experiments.

**2.4 RT-qPCR assay**

Total RNA was extracted from SH-SY5Y cells using TRIzol reagent (cat. no. 9108; Takara Bio, Inc.), following standard operating procedures. Total RNA was reverse transcribed into cDNA using a reverse transcriptase kit (cat. no. R211-01; Vazyme Biotech Co., Ltd.). Subsequently, qPCR was performed using the SYBR Green PCR kit (cat. no. Q311-02; Vazyme Biotech Co., Ltd.), according to the manufacturer's instructions. Glyceraldehyde-3-phosphate dehydrogenase (for mRNA) and uracil 6 (for miRNA) were used as endogenous controls. The relative gene expression was quantified using the 2^ΔΔCt method. Primer sequences are listed in Table 2.

**2.5 Establishment of the oxygen glucose deprivation/reoxygenation (OGD/R) cell model**

To establish an in vitro OGD/R model, the cells were cultured in glucose-free DMEM at 37°C in an atmosphere of 1% O₂, 94% N₂, and 5% CO₂ for 4 h. Subsequently, the cells were cultured under normoxic conditions of 95% air for 2000 transfection reagent for 4 h. Subsequently, the supernatant was discarded and the cells were resuspended in 100 μL FITC-binding buffer. Subsequently, the cell suspension was supplemented with 5 μL ready-to-use annexin V-FITC and 5 μL PI. The cells were incubated for 30 min at room temperature in the dark. Cell apoptosis rate was assessed using a BD FACSCalibur flow cytometer (BD Technologies).

**2.6 Western blotting analysis**

The cells were lysed with the radioimmunoprecipitation assay buffer (cat. no. R0010; Beijing Solarbio Science & Technology Co., Ltd.), and the protein concentration was measured using a bicinchoninic acid kit (cat. no. 3225; Pierce; Thermo Fisher Scientific, Inc.). Equal amounts of proteins were separated via 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes. Following blocking with 5% nonfat milk to prevent nonspecific binding, the membranes were incubated with primary antibodies against XIAP (cat. no. ab21278; dilution, 1:1,000) and GAPDH (cat. no. ab9485; dilution, 1:1,000; both from Abcam) at 4°C overnight. The next day, membranes were incubated with the corresponding secondary antibodies for 2 h. Protein bands were visualized using the ECL method (cat. no. 34579; Applygen Technologies, Inc.).

**2.7 Flow cytometric assay**

Cell apoptosis was evaluated using the Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) Apoptosis Detection Kit (cat. no. 556570; BD Bioscience). Briefly, after treatment, the cells were collected and centrifuged at a high speed and low temperature. Following centrifugation, the supernatant was discarded and the cells were resuspended in 100 μL FITC-binding buffer. Subsequently, the cell suspension was supplemented with 5 μL ready-to-use annexin V-FITC and 5 μL PI. The cells were incubated for 30 min at room temperature in the dark. Cell apoptosis rate was assessed using a BD FACSCalibur flow cytometer (BD Technologies).

**2.8 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay**

Following treatment, cells were seeded into a 96-well plate and incubated for 24 h. Subsequently, each well

---

**Table 2: Primer sequences for PCR**

| Gene name | Sequences: 5′–3′ |
|-----------|----------------|
| IncRNA WT1-AS | Forward, 5′-GCCCTCTGTCTCTTCTTTTG-3′ |
|            | Reverse, 5′-GCTGTTGACCTGGTCTTA-3′ |
| miR-186-5p | Forward, 5′-TCAAGAAGTTCCTTTTGTTGGGT-3′ |
| GAPDH     | Reverse, 5′-CGCTTCCAGATGTGGTCTAC-3′ |
|           | Reverse, 5′-ATACGGCCACCAAGAAGAC-3′ |
| U6        | Reverse, 5′-TTCGGCACGAGTCAG-3′ |
| XIAP      | Reverse, 5′-GTGGTGGCACTATTTCAAGATA-3′ |
was supplemented with 20 μL MTT reagent (5 mg/mL; cat. no. CT02; Sigma-Aldrich), and the cells were cultured for an additional 4 h. The supernatant was discarded and each well was supplemented with 200 μL dimethyl sulfoxide. The absorbance of each well was measured at 570 nm wavelength.

2.9 Caspase 3 activity detection

Caspase 3 activity was assessed using the corresponding detection kit (cat. no. C1116; Beyotime Institute of Biotechnology). Briefly, transfected cells were collected into tubes and centrifuged at 600×g for 5 min at 4°C. The cells were resuspended in an appropriate volume of lysis buffer and lysed for 15 min in an ice bath. Following centrifugation for 10 min, the supernatant was transferred to a pre-cooled centrifuge tube and incubated on ice. The enzymatic activity of caspase 3 was measured immediately at a wavelength of 405 nm.

2.10 Statistical analysis

All experiments were repeated at least three times. All data were analyzed using GraphPad Prism software (version 6.0; GraphPad Software, Inc.). Statistically significant differences between two groups were evaluated using unpaired Student’s t-test, while those among multiple groups were evaluated using one-way analysis of variance followed by Tukey’s post hoc test. Data are expressed as the mean ± standard deviation from three independent experiments. P < 0.05 was considered to be statistically significant.

3 Results

3.1 lncRNA WT1-AS directly interacts with miR-186-5p

First, the association between WT1-AS and miR-186-5p was predicted using the StarBase bioinformatics tool.

Figure 1: Expression levels of lncRNA WT1-AS and miR-186-5p in patients with ischemic stroke. (a) Interaction between miR-186-5p and WT1-AS 3′-UTR was predicted using the Starbase prediction software. (b) Dual luciferase reporter gene assay was used to verify the interaction between WT1-AS and miR-186-5p in 293T cells co-transfected with miR-186-5p mimics and WT or MUT WT1-AS 3′-UTR reporter plasmids. (c and d) Expression levels of WT1-AS and miR-186-5p in blood samples of patients with ischemic stroke and healthy individuals. **P < 0.01 vs control mimics group; ##P < 0.01 vs healthy control group. GraphPad Prism 6.0 software (GraphPad Software, Inc.) was used for creation of the figure.
Bioinformatics analysis revealed that miR-186-5p and lncRNA WT1-AS shared mutual binding sites (Figure 1a), suggesting that miR-186-5p could bind to the WT1-AS 3'-UTR. Subsequently, 293T cells were cotransfected with WT1-AS-WT, WT1-AS-MUT, miR-186-5p, or mimic control for 48 h. A dual-luciferase reporter assay was then performed to evaluate the luciferase activity. The results revealed that miR-186-5p mimics inhibited the activity of WT1-AS-WT but not that of WT1-AS-MUT (Figure 1b). These findings indicate that miR-186-5p is directly targeted by the lncRNA WT1-AS. Subsequently, blood samples from 30 patients with ischemic stroke were collected within 3 h of stroke onset. RT-qPCR assay results demonstrated that, compared with the healthy control group, lncRNA WT1-AS was substantially downregulated (Figure 1c) and miR-186-5p was upregulated (Figure 1d) in the blood samples of patients with ischemic stroke.

3.2 lncRNA WT1-AS levels are downregulated and miR-186-5p levels are upregulated in OGD-induced SH-SY5Y cells

The results showed that, compared with the control group, the expression of lncRNA WT1-AS was significantly reduced in OGD-induced SH-SY5Y cells (Figure 2a), while miR-186-5p expression was significantly upregulated (Figure 2b).

3.3 WT1-AS negatively regulates miR-186-5p levels in SH-SY5Y cells

Compared with the control plasmid group, cell transfection with the WT1-AS plasmid successfully overexpressed WT1-AS in SH-SY5Y cells (Figure 3a). In addition, compared to the mimic control group, transfection with miR-186-5p mimics notably increased miR-186-5p expression in SH-SY5Y cells (Figure 3b). There were no significant changes in the expression of WT1-AS in WT1-AS plasmid + mimic control and WT1-AS plasmid + miR-186-5p mimics groups (Figure 3c). Finally, WT1-AS overexpression inhibited miR-186-5p expression compared to the control plasmid group, while this effect was notably reversed by miR-186-5p overexpression (Figure 3d). The data indicated that WT1-AS negatively regulates miR-186-5p levels in SH-SY5Y cells.

3.4 lncRNA WT1-AS attenuates OGD-induced neuronal injury by downregulating miR-186-5p levels

Compared to the control group, miR-186-5p expression was significantly enhanced in the OGD group. In addition, the expression of miR-186-5p was significantly reduced in the OGD + WT1-AS plasmid group compared to that in the OGD + control plasmid group. However, this effect was reversed by miR-186-5p overexpression (Figure 4a). Furthermore, RT-qPCR analysis showed that compared to the control group, the expression of lncRNA WT1-AS decreased in the OGD group. In addition, compared to the OGD + control plasmid group, lncRNA WT1-AS was upregulated in the OGD + WT1-AS plasmid group (Figure 4b). MTT assay and flow cytometric analysis revealed that compared to the control group, cell viability decreased (Figure 4c) and cell apoptosis increased (Figure 4d and e), respectively, in the OGD group. Compared to the control group, the activity of caspase 3 was enhanced in the OGD group (Figure 4f). Compared to the OGD + control plasmid group, cell viability was significantly increased (Figure 4c), apoptosis (Figure 4d and e) was reduced, and caspase 3 activity was attenuated (Figure 4f).

![Figure 2: Expression levels of lncRNA WT1-AS/miR-186-5p in OGD-induced SH-SY5Y cells. (a) RT-qPCR analysis results showing lncRNA WT1-AS expression levels. (b) RT-qPCR analysis results showing miR-186-5p expression levels. **P < 0.01 vs control group. GraphPad Prism 6.0 software (GraphPad Software, Inc.) was used for creation of the figure.](image-url)
in the OGD + WT1-AS plasmid group. Furthermore, all the aforementioned effects caused by WT1-AS plasmid were reversed following miR-186-5p overexpression. These findings suggested that lncRNA WT1-AS attenuates OGD-induced neuronal injury by downregulating miR-186-5p levels.

3.5 miR-186-5p directly interacts with XIAP

A literature review [19] and bioinformatic analysis using the TargetScan database identified a mutual binding site between miR-186-5p and XIAP (Figure 5a). Furthermore, a dual-luciferase reporter assay verified the association between miR-186-5p and XIAP. As shown in Figure 5b, miR-186-5p mimics inhibited the activity of XIAP-WT but not that of XIAP-MUT. Then, we determined the level of XIAP in the blood samples of patients with ischemic stroke. The results indicated that compared with the healthy control group, XIAP was significantly downregulated (Figure 5c) in the blood samples of patients with ischemic stroke. Taken together, these findings suggest that XIAP is directly targeted by miR-186-5p, and it is downregulated in the blood samples of patients with ischemic stroke.

3.6 miR-186-5p negatively regulated XIAP expression in SH-SY5Y cells

SH-SY5Y cells were transfected with inhibitor control, miR-186-5p inhibitor, control siRNA, XIAP siRNA, miR-186-5p inhibitor + control siRNA, or miR-186-5p inhibitor + XIAP siRNA for 24 h. RT-qPCR was performed to assess the
Figure 4: Effect of lncRNA WT1-AS on OGD-induced nerve cell injury. (a) RT-qPCR analysis results showing microRNA-186-5p expression levels. (b) RT-qPCR analysis results showing lncRNA WT1-AS expression levels. (c) A MTT assay was used to assess the cell viability. (d) A flow cytometric assay was used to evaluate cell apoptosis. (e) The apoptosis ratio is presented. (f) Caspase 3 activity was detected using the corresponding kit. **P < 0.01 vs control group; ##P < 0.01 vs OGD+control mimics group; &&P < 0.01 vs OGD+WT1-AS plasmid+control mimics group. GraphPad Prism 6.0 software (GraphPad Software, Inc.) was used for creation of the figure.

Figure 5: XIAP is directly targeted by miR-186-5p. (a) The interaction between miR-186-5p and XIAP 3′-UTR was predicted by TargetScan. (b) A dual luciferase reporter gene assay was performed to verify the interaction between miR-186-5p and XIAP in 293T cells co-transfected with miR-186-5p mimics and WT or MUT XIAP 3′-UTR reporter plasmids. (c) Expression levels of XIAP in blood samples of patients with ischemic stroke and healthy individuals. **P < 0.01 vs control mimics group; ##P < 0.01 vs Healthy control group. GraphPad Prism 6.0 software (GraphPad Software, Inc.) was used for creation of the figure.
transfection efficiency. Compared to the inhibitor control group, transfection with the miR-186-5p inhibitor significantly reduced miR-186-5p expression in SH-SY5Y cells (Figure 6a). Consistently, compared to the control siRNA group, transfection with XIAP siRNA notably attenuated XIAP expression (Figure 6b). However, miR-186-5p silencing significantly increased the mRNA and protein expression levels of XIAP compared to those in the control inhibitor group, and this effect was reversed by XIAP knockdown (Figure 6c–e). These findings suggest that XIAP is negatively regulated by miR-186-5p in SH-SY5Y cells.

3.7 Effect of miR-186-5p silencing on OGD-induced nerve cell injury

Following cell transfection with inhibitor control, miR-186-5p inhibitor, miR-186-5p inhibitor + control-siRNA, or miR-186-5p inhibitor + XIAP-siRNA for 24 h, an OGD-induced cell injury model was established in SH-SY5Y cells. The results demonstrated that miR-186-5p levels were upregulated (Figure 7a) and XIAP levels were downregulated (Figure 7b) in the OGD group compared to those in the control group. In addition, compared with the OGD + inhibitor control group, the expression of miR-186-5p and XIAP decreased and increased, respectively, in the OGD + miR-186-5p inhibitor group. Finally, compared with the OGD + inhibitor control group, cell viability was improved (Figure 7c) and cell apoptosis (Figure 7d and e) and caspase 3 activity (Figure 7f) were reduced in the OGD + miR-186-5p inhibitor group, and all these effects were reversed by the knockdown of XIAP. In general, miR-186-5p silencing relieves OGD-induced nerve cell injury via up-regulating XIAP expression.

4 Discussion

Acute cerebral ischemic stroke is characterized by an increased mortality rate in humans and is commonly accompanied by several complications, such as behavioral, social, attention,
The pathological process of ischemic stroke is complicated and the factors contributing to the disease are diverse. Neuro-inflammation and oxidative stress have been reported to play significant roles in ischemic brain injury [22,23]. Although several treatment strategies have been previously applied to treat ischemic stroke, the therapeutic potential of currently available treatment approaches remains unsatisfactory [24–26]. Therefore, novel treatment methods for ischemic stroke are urgently required.

The current study aimed to investigate the role of the lncRNA WT1-AS in cerebral ischemic stroke. The roles of lncRNAs in several diseases, including cerebral ischemic stroke, have attracted increasing attention. Shan et al. [27] showed that the lncRNA taurine-upregulated gene 1 (TUG1) is involved in the development of cerebral ischemic stroke, and TUG1 silencing can diminish OGD/R-induced injury. Another study by Wen et al. [28] indicated that lncRNA Gm4419 overexpression upregulates TNF-α, IL-1β, and IL-6 levels, thereby enhancing OGD/R damage. Hu et al. [29] showed that knockdown of lncRNA small nucleolar RNA host gene 15 could improve ischemia/hypoxia-induced neuronal injury and microglial inflammation by targeting the miR-302a-3p/signal transducer and activator of transcription 1 axis. Furthermore, Xiao et al. [30] demonstrated that lncRNA H19 was significantly upregulated in patients with ischemic stroke, whereas its silencing could attenuate neuronal apoptosis in OGD-induced neuronal cells by

Figure 7: miR-186-5p inhibitor attenuates OGD-induced neuronal injury by upregulating XIAP expression. (a) RT-qPCR analysis results showing miR-186-5p expression levels. (b) RT-qPCR analysis results showing XIAP expression levels. (c) MTT assay was used to assess the cell viability. (d) Flow cytometric assay was carried out to evaluate cell apoptosis. (e) The cell apoptosis ratio is presented. (f) Caspase 3 activity was detected using the corresponding kit. **P < 0.01 vs control group; #P < 0.01 vs OGD + inhibitor control group; ##P < 0.01 vs OGD + miR-186-5p inhibitor + control siRNA group. GraphPad Prism 6.0 software (GraphPad Software, Inc.) was used for creation of the figure.
targeting miR-19a. In this study, bioinformatics analysis and dual-luciferase reporter assays were performed to verify the interaction between lncRNA WT1-AS and miR-186-5p.

In this study, we found that IncRNA WT1-AS reduced OGD-induced SH-SY5Y cell injury via the miR-186-5p/XIAP axis, indicating the protective role of IncRNA WT1-AS in hypoxia/ischemia-induced neuronal injury in cerebral ischemic stroke.

Abbreviations

FITC fluorescein isothiocyanate
lncRNA long non-coding RNA
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
OGD oxygen glucose deprivation
PI propidium iodide
RT-qPCR reverse transcription-quantitative PCR
WT1-AS WT1 antisense RNA
XIAP X-linked inhibitor of apoptosis

Acknowledgments: Not applicable.

Funding information: This study was supported by the Taizhou Science and Technology Support Plan (Social Development, grant no. SSF20210117), the Scientific Research Foundation of Taizhou People’s Hospital (Grant No. ZL202015) and the Project of Taizhou City Personnel Bureau (Grant No. RCPY201937).

Conflict of interest: Authors state no conflict of interest.

Data availability statement: The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.
References

[1] Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke. Stroke. 2014;45:3754–832.

[2] Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics–2020 update: a report from the american heart association. Circulation. 2020;141:e139–596.

[3] Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA. Incidence of the major stroke subtypes: initial findings from the North East Melbourne stroke incidence study (NEMESIS). Stroke. 2001;32:1732–8.

[4] Kuriakose D, Xiao Z. Pathophysiology and treatment of stroke: Present status and future perspectives. Int J Mol Sci. 2020;21:7609.

[5] Rinn JL, Chang HY. Long noncoding RNAs: molecular modalities to organizational functions. Annu Rev Biochem. 2020;89:283–308.

[6] Leotta E, Hall J. Noncoding RNAs in disease. FEBs Lett. 2018;592:2884–900.

[7] Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393–407.

[8] Carter G, Miladinovic B, Patel AA, Deland L, Mastorides S, Qiu G, Tong W, Jiang C, Xie Q, Zou J, Luo C, et al. Long noncoding RNA WT1 3p regulates cell proliferation, apoptosis, migration and invasion via PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer. Onco Targets Ther. 2021;14:891–596.

[9] Luo H, Zhang J, He Z, Wu S. Long noncoding RNA WT1 3p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells. BMC Cancer. 2018;18:421.
[35] Zhu K, Wang L, Zhang X, Sun H, Chen T, Sun C, et al. LncRNA HCP5 promotes neuroblastoma proliferation by regulating miR-186-5p/MAP3K2 signal axis. J Pediatr Surg. 2021;56:778–87.

[36] Zhang Z, Zhang W, Mao J, Xu Z, Fan M. miR-186-5p functions as a tumor suppressor in human osteosarcoma by targeting FOXX1. Cell Physiol Biochem. 2019;52:553–64.

[37] Jost PJ, Vucic D. Regulation of cell death and immunity by XIAP. Cold Spring Harb Perspect Biol. 2020;12:a036426.

[38] Tu H, Costa M. XIAP’s profile in human cancer. Biomolecules. 2020;10:1493.

[39] Huang L, Liu Z, Hu J, Luo Z, Zhang C, Wang L, et al. MiR-377-3p suppresses colorectal cancer through negative regulation on Wnt/beta-catenin signaling by targeting XIAP and ZEB2. Pharmacol Res. 2020;156:104774.

[40] Deng W, Fan C, Zhao Y, Mao Y, Li J, Zhang Y, et al. MicroRNA-130a regulates neurological deficit and angiogenesis in rats with ischaemic stroke by targeting XIAP. J Cell Mol Med. 2020;24:10987–1000.